Publications

Skip to content

New and Noteworthy

Explore our latest insights, research, and stories

Flatiron Health redefines real-world evidence: Pioneering scientific innovations move beyond 'what is' to uncover 'why' and predict 'what will be'

Real-world evidence
Data science
Press releases

The future of ctDNA in cancer care: real-world signals, real clinical impact
Data You Can Trust: Setting the Bar for ML/LLM-Extracted RWD
Can You Trust Real-World Data Extracted by a Large Language Model (LLM)?

Featured topics

Real-world evidence
Clinical research
Point of care
Flatiron stories
Clinical decision support
Video
Machine learning
Press releases
Post marketing requirements
HTA and market access
Health equity
Case study
EHR-to-EDC

All the latest

Topics

Artificial intelligence

Clinical decision support

Clinical research

Inclusion

Data management

Drug Discovery

EHR-to-EDC

Flatiron stories

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Patient identification

Point of Care

Post marketing requirements

Practice management

Precision medicine

Prospective study

Protocol optimization

Real-World Evidence

Regulatory

Site identification

Technology & Engineering

Treatment patterns

Trial design

Unmet need

Value-based care

Content type

Article

Press releases

Case study

Publications

Customer interviews

Event recap

Video

Podcast

Showing 9 of 0 results

Flatiron Health redefines real-world evidence: Pioneering scientific innovations move beyond 'what is' to uncover 'why' and predict 'what will be'
Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practice
ESMO
Real-world treatment patterns and outcomes in US patients with neurotrophic tyrosine receptor kinase–positive solid tumors
ESMO
The future of ctDNA in cancer care: real-world signals, real clinical impact
From Obligation to Opportunity: Accelerating Safety Evidence Using Digital and Pragmatic Solutions
Data You Can Trust: Setting the Bar for ML/LLM-Extracted RWD
Can You Trust Real-World Data Extracted by a Large Language Model (LLM)?
Key considerations for assessing real-world comparative effectiveness in the context of the Drug Price Negotiation program: A case study of pembrolizumab
PharmaEconomics
- Comparative effectiveness
- Non-small cell lung cancer
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
ESMO Open

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2025